Dr. Omid Omidvar, MD

Dr. Omidvar practices at Southland Neurologic Institute a Medical Corporation in Long Beach, California.

Dr. Omidvar's NPI, 1184678583, was assigned on May 20, 2006. Dr. Omidvar graduated from Other in 1992. Dr. Omidvar holds California license A55552.

Dr. Omidvar's primary practice is Southland Neurologic Institute a Medical Corporation, at 3747 Worsham Ave, Long Beach, CA 90808 in Los Angeles County. The practice phone is (562) 430-4513.

Dr. Omidvar's primary practice is Southland Neurologic Institute a Medical Corporation in Long Beach, California. Dr. Omidvar is also affiliated with Long Beach Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Omidvar to 4 more hospitals, 1 group practice or clinic, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Omidvar practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Omidvar's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Omidvar is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Omidvar is licensed in California.

Dmand AI lists alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, encephalopathy, epilepsy, essential tremor, fibromyalgia and chronic pain and head injury among the conditions Dr. Omidvar treats.

CMS data shows 2,527 Medicare services from Dr. Omidvar across 14 procedure codes in 2024, for 867 Medicare patients. Medicare paid $254,502 for them.

CMS counts 867 Medicare patients who saw Dr. Omidvar in 2024. The largest group is 75 to 84, with 352 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 38% are also on Medicaid. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Omidvar's median patient age at 72, with 54% women.

In 2024, Dr. Omidvar wrote 3,241 Medicare Part D claims for 395 patients. 84% of them were for generic drugs. CMS names the drug for 2,819 of them, across 69 drugs with 11 or more claims each, at $724,191 in total drug cost. In 2023, CMS named 2,652 claims across 67 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Omidvar for performance year 2024, reported individually. Dr. Omidvar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Omidvar as offering telehealth.

Dmand AI links 4 papers to Dr. Omidvar, published from 2018 to 2022. 2018 was the busiest year, with 2. The most frequent topics are Double-Blind Method, Friedreich Ataxia and Linoleic Acid. Dr. Omidvar has published most often in Mov Disord. Dr. Omidvar's most frequent co-authors are Theresa A. Zesiewicz, MD, Jason Lamar Aldred, MD and Aaron L. Ellenbogen, DO.

Dmand AI links Dr. Omidvar to 11 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Alzheimer Disease, Tauopathies and Parkinson Disease. Eli Lilly and Company sponsors the most, 5. Open Payments lists research payments to Dr. Omidvar that name 4 trials.

CMS Open Payments shows 821 general payments to Dr. Omidvar from 70 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 77% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,221. It also lists 10 research payments totaling $16,914 from 2016 to 2023, naming 4 clinical trials.

Dmand AI lists 3 awards for Dr. Omidvar, most recently Regional Top Doctor in 2019.

Dr. Omidvar graduated from Other in 1992. Dr. Omidvar is a member of AAN.

Dr. Omidvar is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.